Latest Breaking News On - Aquilo capital management - Page 1 : comparemela.com

Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United kingdomMichael amorosoAzercabtagene zapreleucelGene insertion programElimination programDevelopment expensesViral elimination programAquilo capital managementUniversity of pennsylvania gene therapy programDrug administrationTherapeutics incPrecision biosciences incPrecision biosciencesChief executive officerPrevail therapeuticsOwned portfolio

Precision BioSciences Announces $40 0 Million Offering of Common Stock and Warrants

Precision BioSciences Announces $40 0 Million Offering of Common Stock and Warrants
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesExchange commissionPrecision biosciences incAquilo capital managementEquity syndicate departmentGuggenheim securitiesPrecision biosciencesPerceptive advisorsJanus henderson investorsAnnual reportQuarterly reportsCurrent reports

Spero Therapeutics, Inc (NASDAQ:SPRO) Expected to Post Quarterly Sales of $2 65 Million

Brokerages expect Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Rating) to report sales of $2.65 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Spero Therapeutics’ earnings. The lowest sales estimate is $2.30 million and the highest is $3.00 million. Spero Therapeutics posted sales of $5.15 million during the […]

United statesBerenberg bankGoldman sachs group incZacks investment researchSpero therapeutics company profile get ratingBlackrock incMarshall waceWells fargo companyCantor fitzgeraldSpero therapeutics incAquilo capital management llcBarclays plcSpero therapeuticsGet ratingZacks investmentSpero therapeutic

Spero Therapeutics, Inc (NASDAQ:SPRO) Sees Large Drop in Short Interest

Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Rating) was the target of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 1,650,000 shares, a decline of 55.3% from the April 30th total of 3,690,000 shares. Based on an average daily volume of 634,900 shares, the […]

Nova scotiaUnited statesSecurities exchange commissionBerenberg bankZacks investment researchBlackrock incPatriot financial group insurance agencyGranahan investment management incCantor fitzgeraldSpero therapeutics incAquilo capital management llcBarclays plcRoyal bankSpero therapeuticsGet ratingAquilo capital management

-$0 77 EPS Expected for Spero Therapeutics, Inc (NASDAQ:SPRO) This Quarter

Wall Street analysts expect Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Rating) to announce earnings of ($0.77) per share for the current quarter, according to Zacks. Two analysts have issued estimates for Spero Therapeutics’ earnings. The lowest EPS estimate is ($0.90) and the highest is ($0.56). Spero Therapeutics posted earnings per share of ($0.63) during the […]

United statesAllspring global investments holdingsSecurities exchange commissionBerenberg bankZacks investment researchMarshall wacePatriot financial group insurance agencyCantor fitzgeraldSpero therapeutics incAquilo capital management llcBarclays plcWall streetSpero therapeuticsGet ratingSpero therapeuticInvestment research